THE ROLE OF PLASMA-LEVEL MONITORING IN CANCER-CHEMOTHERAPY

被引：1

作者：

DONEHOWER, RC ^{[1
]}

ERLICHMAN, C ^{[1
]}

机构：

[1] PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA

来源：

关键词：

D O I：

10.1016/0165-6147(81)90265-0

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：64 / 66

页数：3

共 11 条

[1] ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P73
[2] BLEYER WA, 1978, CANCER-AM CANCER SOC, V41, P36, DOI 10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO
[3] 2-I
[4] CHABNER BA, 1977, SEMIN ONCOL, V4, P165
[5] CROOKE ST, 1977, CANCER TREAT REP, V61, P1631
[6] FINN C, 1975, CANCER CHEMOTH REP 1, V59, P279
[7] MURINSON D, 1978, CLIN PHARMACOLOGY AN, P163
[8] PINEDO HM, 1976, CANCER RES, V36, P4418
[9] SPEYER JL, 1980, CANCER RES, V40, P567
[10] USE OF PLASMA PHARMACOKINETICS TO PREDICT AND PREVENT METHOTREXATE TOXICITY
STOLLER, RG
HANDE, KR
JACOBS, SA
ROSENBERG, SA
CHABNER, BA
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (12) : 630 - 634